Diamond-Blackfan anemia natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| (5 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
[[Diamond-Blackfan anemia|DBA]] typically present with common symptoms of [[anemia]], including [[Pallor|pale]] [[skin]], [[sleepiness]], [[irritability]], [[tachycardia]]. Common [[complications]] of [[Diamond-Blackfan anemia|DBA]] include physical abnormalities, [[Cancer]] predisposition, [[eye]] problems such as [[cataracts]], [[glaucoma]], or [[strabismus]], kidney abnormalities, [[hypospadias]], and secondary [[complications]] due to standard therapies( [[Corticosteroids]] treatment, Red cell [[transfusion]], [[Bone marrow transplantation]]). [[Prognosis]] is relatively good, overall actuarial survival is 75% at age 40 years | |||
==Diamond-Blackfan anemia natural history, complications and prognosis== | ==Diamond-Blackfan anemia natural history, complications and prognosis== | ||
===Natural history=== | |||
*DBA typically presents in infancy, most commonly with [[pallor]] and [[lethargy]], median age at presentation is 8 weeks. [[Hydrops fetalis]] in some cases have been seen.<ref name="pmid23349008">{{cite journal |vauthors=Da Costa L, Chanoz-Poulard G, Simansour M, French M, Bouvier R, Prieur F, Couque N, Delezoide AL, Leblanc T, Mohandas N, Touraine R |title=First de novo mutation in RPS19 gene as the cause of hydrops fetalis in Diamond-Blackfan anemia |journal=Am. J. Hematol. |volume=88 |issue=2 |pages=160 |date=February 2013 |pmid=23349008 |doi=10.1002/ajh.23366 |url=}}</ref><ref name="pmid29599205">{{cite journal |vauthors=Wlodarski MW, Da Costa L, O'Donohue MF, Gastou M, Karboul N, Montel-Lehry N, Hainmann I, Danda D, Szvetnik A, Pastor V, Paolini N, di Summa FM, Tamary H, Quider AA, Aspesi A, Houtkooper RH, Leblanc T, Niemeyer CM, Gleizes PE, MacInnes AW |title=Recurring mutations in RPL15 are linked to hydrops fetalis and treatment independence in Diamond-Blackfan anemia |journal=Haematologica |volume=103 |issue=6 |pages=949–958 |date=June 2018 |pmid=29599205 |pmc=6058779 |doi=10.3324/haematol.2017.177980 |url=}}</ref> | *[[DBA]] typically presents in [[infancy]], most commonly with [[pallor]] and [[lethargy]], median age at presentation is 8 weeks. [[Hydrops fetalis]] in some cases have been seen.<ref name="pmid23349008">{{cite journal |vauthors=Da Costa L, Chanoz-Poulard G, Simansour M, French M, Bouvier R, Prieur F, Couque N, Delezoide AL, Leblanc T, Mohandas N, Touraine R |title=First de novo mutation in RPS19 gene as the cause of hydrops fetalis in Diamond-Blackfan anemia |journal=Am. J. Hematol. |volume=88 |issue=2 |pages=160 |date=February 2013 |pmid=23349008 |doi=10.1002/ajh.23366 |url=}}</ref><ref name="pmid29599205">{{cite journal |vauthors=Wlodarski MW, Da Costa L, O'Donohue MF, Gastou M, Karboul N, Montel-Lehry N, Hainmann I, Danda D, Szvetnik A, Pastor V, Paolini N, di Summa FM, Tamary H, Quider AA, Aspesi A, Houtkooper RH, Leblanc T, Niemeyer CM, Gleizes PE, MacInnes AW |title=Recurring mutations in RPL15 are linked to hydrops fetalis and treatment independence in Diamond-Blackfan anemia |journal=Haematologica |volume=103 |issue=6 |pages=949–958 |date=June 2018 |pmid=29599205 |pmc=6058779 |doi=10.3324/haematol.2017.177980 |url=}}</ref>The severity of [[Diamond-Blackfan anemia]] may vary, even within the same family. | ||
===Complications=== | |||
*Common complications of [[Diamond-Blackfan anemia]] include: | |||
*Common complications of Diamond | |||
*Physical abnormalities | *Physical abnormalities | ||
*higher-than-average chance of developing myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) bone cancer (osteosarcoma), colon cancer<ref name="pmid20012593">{{cite journal |vauthors=Luft F |title=The rise of a ribosomopathy and increased cancer risk |journal=J. Mol. Med. |volume=88 |issue=1 |pages=1–3 |date=January 2010 |pmid=20012593 |doi=10.1007/s00109-009-0570-0 |url=}}</ref> | *higher-than-average chance of developing [[myelodysplastic syndrome]] ([[MDS]]), [[acute myeloid leukemia]] ([[AML]]), [[bone cancer]] ([[osteosarcoma]]), [[colon cancer]]<ref name="pmid20012593">{{cite journal |vauthors=Luft F |title=The rise of a ribosomopathy and increased cancer risk |journal=J. Mol. Med. |volume=88 |issue=1 |pages=1–3 |date=January 2010 |pmid=20012593 |doi=10.1007/s00109-009-0570-0 |url=}}</ref> | ||
*Eye problems such as [[cataracts]], [[glaucoma]], or [[strabismus]] | *Eye problems such as [[cataracts]], [[glaucoma]], or [[strabismus]] | ||
*[[kidney]] abnormalities | *[[kidney]] abnormalities | ||
*[[hypospadias]] | *[[hypospadias]] | ||
*Secondary complications due to standard therapies( Corticosteroids treatment, Red cell transfusion, Bone | *Secondary [[complications]] due to standard therapies( [[Corticosteroids]] treatment, [[Red cell transfusion]], [[Bone marrow transplantation]]): | ||
**Transfusion iron overload | **Oragans involvement due to [[Transfusion]] [[iron overload]] | ||
***Cirrhosis or fibrosis of the liver | ***[[Cirrhosis]] or [[fibrosis]] of the [[liver]] | ||
***Cardiac arrythmias | ***[[Cardiac arrythmia|Cardiac arrythmias]] | ||
***Diabetes | ***[[Diabetes]] | ||
***Reproductive organ failure | ***[[Reproductive organ]] failure | ||
***Growth stunting | ***[[Growth]] stunting | ||
***Endocrine failure affecting the thyroid and adrenal | ***[[Endocrine]] failure affecting the [[thyroid]] and [[adrenal]] | ||
**Side effects of corticosteroids | **Side effects of [[corticosteroids]] | ||
***[[Osteoporosis]] | ***[[Osteoporosis]] | ||
***Weight gain | ***[[Weight gain]] | ||
***Cushingoid appearance | ***[[Cushingoid appearance]] | ||
***Hypertension | ***Hypertension | ||
***[[Diabetes mellitus]] | ***[[Diabetes mellitus]] | ||
***Growth retardation | ***[[Growth retardation]] | ||
***Pathologic bone fractures | ***[[Pathologic]] [[bone fractures]] | ||
***[[Gastric ulcers]] | ***[[Gastric ulcers]] | ||
***[[Cataracts]] | ***[[Cataracts]] | ||
***[[Glaucoma]] | ***[[Glaucoma]] | ||
***Increased susceptibility to infection | ***Increased susceptibility to [[infection]] | ||
**Stem cell transplantation | **Stem cell transplantation | ||
***Graft vs. Host Disease (GVHD) | ***[[Graft vs. Host Disease]] ([[GVHD]]) | ||
***Rejection | ***[[Rejection]] | ||
===Prognosis=== | |||
[[Prognosis]] is relatively good, overall actuarial survival is 75% at age 40 years, but complications related to treatment may alter the quality of life of the affected individuals. Severe complications as a result of treatment or the development of [[cancer]] may reduce [[life expectancy]]. <ref name="pmid31424886">{{cite journal |vauthors=Gadhiya K, Budh DP |title= |journal= |volume= |issue= |pages= |date= |pmid=31424886 |doi= |url=}}</ref> | |||
*Ultimately, 40% of case subjects remain dependent upon [[corticosteroids]] which increase the risk of [[heart disease]], [[osteoporosis]], and severe [[infections]]. <ref name="pmid20960466">{{cite journal |vauthors=Boria I, Garelli E, Gazda HT, Aspesi A, Quarello P, Pavesi E, Ferrante D, Meerpohl JJ, Kartal M, Da Costa L, Proust A, Leblanc T, Simansour M, Dahl N, Fröjmark AS, Pospisilova D, Cmejla R, Beggs AH, Sheen MR, Landowski M, Buros CM, Clinton CM, Dobson LJ, Vlachos A, Atsidaftos E, Lipton JM, Ellis SR, Ramenghi U, Dianzani I |title=The ribosomal basis of Diamond-Blackfan Anemia: mutation and database update |journal=Hum. Mutat. |volume=31 |issue=12 |pages=1269–79 |date=December 2010 |pmid=20960466 |pmc=4485435 |doi=10.1002/humu.21383 |url=}}</ref> | *Ultimately, 40% of case subjects remain dependent upon [[corticosteroids]] which increase the risk of [[heart disease]], [[osteoporosis]], and severe [[infections]]. <ref name="pmid20960466">{{cite journal |vauthors=Boria I, Garelli E, Gazda HT, Aspesi A, Quarello P, Pavesi E, Ferrante D, Meerpohl JJ, Kartal M, Da Costa L, Proust A, Leblanc T, Simansour M, Dahl N, Fröjmark AS, Pospisilova D, Cmejla R, Beggs AH, Sheen MR, Landowski M, Buros CM, Clinton CM, Dobson LJ, Vlachos A, Atsidaftos E, Lipton JM, Ellis SR, Ramenghi U, Dianzani I |title=The ribosomal basis of Diamond-Blackfan Anemia: mutation and database update |journal=Hum. Mutat. |volume=31 |issue=12 |pages=1269–79 |date=December 2010 |pmid=20960466 |pmc=4485435 |doi=10.1002/humu.21383 |url=}}</ref> | ||
*Another 40% become dependent upon red cell transfusions which require regular [[chelation]] to prevent [[iron overload]] and increases the risk of alloimmunization and transfusion reactions, and can cause severe co-morbidities.<ref name="pmid23016900">{{cite journal |vauthors=Horos R, von Lindern M |title=Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia |journal=Br. J. Haematol. |volume=159 |issue=5 |pages=514–27 |date=December 2012 |pmid=23016900 |doi=10.1111/bjh.12058 |url=}}</ref> | *Another 40% become dependent upon [[red cell transfusions]] which require regular [[chelation]] to prevent [[iron overload]] and increases the risk of [[alloimmunization]] and [[transfusion reactions]], and can cause severe co-morbidities.<ref name="pmid23016900">{{cite journal |vauthors=Horos R, von Lindern M |title=Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia |journal=Br. J. Haematol. |volume=159 |issue=5 |pages=514–27 |date=December 2012 |pmid=23016900 |doi=10.1111/bjh.12058 |url=}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 01:04, 26 September 2020
|
Diamond-Blackfan anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diamond-Blackfan anemia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Diamond-Blackfan anemia natural history, complications and prognosis |
|
FDA on Diamond-Blackfan anemia natural history, complications and prognosis |
|
CDC on Diamond-Blackfan anemia natural history, complications and prognosis |
|
Diamond-Blackfan anemia natural history, complications and prognosis in the news |
|
Blogs on Diamond-Blackfan anemia natural history, complications and prognosis |
Overview
DBA typically present with common symptoms of anemia, including pale skin, sleepiness, irritability, tachycardia. Common complications of DBA include physical abnormalities, Cancer predisposition, eye problems such as cataracts, glaucoma, or strabismus, kidney abnormalities, hypospadias, and secondary complications due to standard therapies( Corticosteroids treatment, Red cell transfusion, Bone marrow transplantation). Prognosis is relatively good, overall actuarial survival is 75% at age 40 years
Diamond-Blackfan anemia natural history, complications and prognosis
Natural history
- DBA typically presents in infancy, most commonly with pallor and lethargy, median age at presentation is 8 weeks. Hydrops fetalis in some cases have been seen.[1][2]The severity of Diamond-Blackfan anemia may vary, even within the same family.
Complications
- Common complications of Diamond-Blackfan anemia include:
- Physical abnormalities
- higher-than-average chance of developing myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), bone cancer (osteosarcoma), colon cancer[3]
- Eye problems such as cataracts, glaucoma, or strabismus
- kidney abnormalities
- hypospadias
- Secondary complications due to standard therapies( Corticosteroids treatment, Red cell transfusion, Bone marrow transplantation):
- Oragans involvement due to Transfusion iron overload
- Cirrhosis or fibrosis of the liver
- Cardiac arrythmias
- Diabetes
- Reproductive organ failure
- Growth stunting
- Endocrine failure affecting the thyroid and adrenal
- Side effects of corticosteroids
- Osteoporosis
- Weight gain
- Cushingoid appearance
- Hypertension
- Diabetes mellitus
- Growth retardation
- Pathologic bone fractures
- Gastric ulcers
- Cataracts
- Glaucoma
- Increased susceptibility to infection
- Stem cell transplantation
- Oragans involvement due to Transfusion iron overload
Prognosis
Prognosis is relatively good, overall actuarial survival is 75% at age 40 years, but complications related to treatment may alter the quality of life of the affected individuals. Severe complications as a result of treatment or the development of cancer may reduce life expectancy. [4]
- Ultimately, 40% of case subjects remain dependent upon corticosteroids which increase the risk of heart disease, osteoporosis, and severe infections. [5]
- Another 40% become dependent upon red cell transfusions which require regular chelation to prevent iron overload and increases the risk of alloimmunization and transfusion reactions, and can cause severe co-morbidities.[6]
References
- ↑ Da Costa L, Chanoz-Poulard G, Simansour M, French M, Bouvier R, Prieur F, Couque N, Delezoide AL, Leblanc T, Mohandas N, Touraine R (February 2013). "First de novo mutation in RPS19 gene as the cause of hydrops fetalis in Diamond-Blackfan anemia". Am. J. Hematol. 88 (2): 160. doi:10.1002/ajh.23366. PMID 23349008.
- ↑ Wlodarski MW, Da Costa L, O'Donohue MF, Gastou M, Karboul N, Montel-Lehry N, Hainmann I, Danda D, Szvetnik A, Pastor V, Paolini N, di Summa FM, Tamary H, Quider AA, Aspesi A, Houtkooper RH, Leblanc T, Niemeyer CM, Gleizes PE, MacInnes AW (June 2018). "Recurring mutations in RPL15 are linked to hydrops fetalis and treatment independence in Diamond-Blackfan anemia". Haematologica. 103 (6): 949–958. doi:10.3324/haematol.2017.177980. PMC 6058779. PMID 29599205.
- ↑ Luft F (January 2010). "The rise of a ribosomopathy and increased cancer risk". J. Mol. Med. 88 (1): 1–3. doi:10.1007/s00109-009-0570-0. PMID 20012593.
- ↑ Gadhiya K, Budh DP. PMID 31424886. Missing or empty
|title=(help) - ↑ Boria I, Garelli E, Gazda HT, Aspesi A, Quarello P, Pavesi E, Ferrante D, Meerpohl JJ, Kartal M, Da Costa L, Proust A, Leblanc T, Simansour M, Dahl N, Fröjmark AS, Pospisilova D, Cmejla R, Beggs AH, Sheen MR, Landowski M, Buros CM, Clinton CM, Dobson LJ, Vlachos A, Atsidaftos E, Lipton JM, Ellis SR, Ramenghi U, Dianzani I (December 2010). "The ribosomal basis of Diamond-Blackfan Anemia: mutation and database update". Hum. Mutat. 31 (12): 1269–79. doi:10.1002/humu.21383. PMC 4485435. PMID 20960466.
- ↑ Horos R, von Lindern M (December 2012). "Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia". Br. J. Haematol. 159 (5): 514–27. doi:10.1111/bjh.12058. PMID 23016900.